Results 101 to 110 of about 8,055 (251)

Successful Treatment of Hypothalamic Obesity with Tirzepatide

BACKGROUND/OBJECTIVE: Hypothalamic obesity (HO) is a rare but severe form of obesity characterized by hypothalamic damage resulting in hyperphagia and decreased energy expenditure.
Mullally, Jamie A., Brijmohan, Sharmela
core   +1 more source

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

British Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo, Veronica Casale, Roberta d'Emmanuele di Villa Bianca, Valentina Vellecco, Mariarosaria Bucci   +4 more
wiley   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

British Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral, Nicholas Monaco, Daniel I. Brierley, Monica Imbernon   +3 more
wiley   +1 more source

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase 3b,
Gomez Valderas, E., Horn, D.B., Das, S., Aronne, L.J., Dunn, J.P., Falcon, B.L., Lee, C.J., Glass, L.C., Senyucel, C., le Roux, C.W., Ho, W.   +10 more
core   +1 more source

The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis

BMC Medicine
Background Tirzepatide is a dual-acting glucagon-like peptide-1 analog and a glucose-dependent insulinotropic polypeptide analog. The disease-specific weight-reducing effects associated with tirzepatide use are well established, but its adverse effects ...
Christina Dam Bjerregaard Sillassen, Pascal Faltermeier, Jonas Leth Bjerg, Rebecca Kjær Andersen, Johanne Juul Petersen, Patrick Bjerregaard Andersen, Caroline Barkholt Kamp, Fredric Karlsson, Johannes Grand, Helena Dominguez, Anne Frølich, Peter Gæde, Christian Gluud, Ole Mathiesen, Janus Christian Jakobsen   +14 more
doaj   +1 more source

Evaluation of a secondary care multidisciplinary clinic for adults with early‐onset type 2 diabetes at high risk in Leicester, Leicestershire and Rutland

Diabetic Medicine, EarlyView.
Abstract Background Clinical services for adults with early‐onset type 2 diabetes (EOT2D) are in urgent need of improvement. Methods We evaluated a multi‐disciplinary clinic for individuals with EOT2D at high risk (HbA1c >9%/triglyceride >20 mmol/L), providing 2–3 flexibly arranged consultations per individual between March 2024 and September 2025 ...
Jonathan Goldney, Malak Hamza, Priscilla Sarkar, Harriet Morgan, Nicole Green, James Ridgeway, Victoria Alabraba, Laura Willcocks, Krupali Chandracant, Kashmala Javed, Rhys O'Callaghan, Finley Turner, Samuel Seidu, Claire L. Meek, Melanie J. Davies   +14 more
wiley   +1 more source

Tirzepatide Versus Long-Acting Insulin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Journal of Diabetology
Introduction: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like-peptide-1 receptor agonist (GLP-1 RA), has emerged as a promising option for managing type 2 diabetes.
Mohamed A. Abu-Alsaud, Mohamed Ellebedy, Noha Hammad, Mina I. Lamie, Ahmed F. El-Rawy   +4 more
doaj   +1 more source

Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity [PDF]

BACKGROUND: Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment.
Fietze, Ingo, Schwab, Richard J, Azarbarzin, Ali, Dunn, Julia P, Bunck, Mathijs C, Weaver, Terri E, Grunstein, Ronald R, Chakladar, Sujatro, Redline, Susan, Malhotra, Atul, Sands, Scott A, Bednarik, Josef   +11 more
core   +1 more source

Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Tirzepatide is a once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large ...
Theresa Hunter Gibble, Malvika Venkataraman, Donna Mojdami, Carlos Vallarino, Grace Stockbower, Michael Grabner, Mythili Ananth, Karishma Desai   +7 more
wiley   +1 more source

The promise of tirzepatide: A narrative review of metabolic benefits

Obesity and type 2 diabetes mellites (T2DM) are intertwined epidemics that continue to pose significant challenges to global public health. We aim to review the available evidence on the metabolic effects of tirzepatide, focusing on weight loss and ...
Sokary, Sara, Bawadi, Hiba
core   +1 more source